To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dexcom CEO Kevin Sayer shared new data on the company’s first over-the-counter glucose sensor at the J.P ...

BofA Securities maintained a Buy rating on DexCom (NASDAQ:DXCM) shares, with a steady price target of $90.00. The firm's analysts suggest the current market movement presents an appealing opportunity ...

Pacelli, A Former Executive of Dexcom, Inc., Will Lead Epitel Into Its Next Phase of Growth ...

Dexcom CEO Kevin Sayer shared new data on the company’s first over-the-counter glucose sensor at the J.P. Morgan Healthcare Conference on Monday. Stelo, which is indicated for people who don’t take ...

The medical device company has seen its growth rate take a hit in recent quarters. DexCom blames its restructuring, but rising demand for GLP-1 drugs could be an issue. The stock's valuation has ...

DexCom, Inc.'s growth is impressive but limited by its niche market, with my projected ceiling being ~$7.5bn in peak annual revenues. Despite positive Q4 2024 results, DexCom's stock is fairly ...

Dexcom (DXCM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 13. Analyst Mike Kratky from ...

Baird has upgraded DexCom (NASDAQ:DXCM) to outperform from neutral, citing increasing confidence in the company's ability to return revenue growth to the low-to-mid teens by mid-2025. The ...